CytomX Therapeutics, Inc.

Develops tumor-activated antibody therapeutics for more targeted, less toxic cancer treatments.

CTMX | NDAQ

Overview

Corporate Details

ISIN(s):: US23284F1057
LEI:
Country:: United States of America
Address:: 151 OYSTER POINT BLVD., 94080 SOUTH SAN FRANCISCO
Website:: https://cytomx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing a novel class of investigational antibody therapeutics. The company's core technology is its proprietary Probody® platform, which is designed to create conditionally activated biologics. These therapeutics remain masked and inactive in healthy tissue but are activated specifically within the tumor microenvironment. This approach aims to enhance the therapeutic window, enabling more potent and targeted anti-cancer treatments with potentially reduced toxicity. CytomX is advancing a deep pipeline of Probody therapeutics, both independently and through strategic collaborations, to bring new treatment options to cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CytomX Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CytomX Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CytomX Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Coherus Oncology, Inc. Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.	United States of America	CHRS
COLLEGIUM PHARMACEUTICAL, INC Develops and commercializes abuse-deterrent medications for responsible chronic pain management.	United States of America	COLL
CollPlant Biotechnologies Ltd Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.	United States of America	CLGN
Compass Therapeutics, Inc. A clinical-stage oncology firm developing antibody therapies that engage the immune system.	United States of America	CMPX
Compugen Ltd. Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.	Israel	CGEN
COMPUGEN LTD AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.	United States of America	CGEN
Connect Biopharma Holdings Ltd Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.	United States of America	CNTB
Context Therapeutics Inc. Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.	United States of America	CNTX
Contineum Therapeutics, Inc. Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.	United States of America	CTNM
CORCEPT THERAPEUTICS INC Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.	United States of America	CORT